Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Merkel Cell × lutetium Lu 177 dotatate × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 18 Meningioma 5 Gastro-enteropancreatic neuroendocrine tumor 5 Adenoma, Islet Cell 3 Pheochromocytoma 2 Paraganglioma 2 Somatostatinoma 1 Somatostatin Receptor-positive Neuroendocrine Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Medulloblastoma 1 Hypertension 1 Glioma 1 Glioblastoma 1 Extensive Stage Small Cell Lung Cancer 1 Ependymoma 1 Disease Progression 1 Digestive System Neuroendocrine Tumor G1 1 Diffuse Intrinsic Pontine Glioma 1 Central Nervous System Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma, Merkel Cell 1 Carcinoid Tumor 1 Advanced Neuroendocrine Neoplasm 1 Advanced Lung Neuroendocrine Tumor 1

Interventions

pembrolizumab 16 Nivolumab 12 avelumab 8 Ipilimumab 6 Specimen Handling 5 Biopsy 5 atezolizumab 4 Magnetic Resonance Spectroscopy 4 cemiplimab 3 Cyclophosphamide 3 poly ICLC 2 fludarabine phosphate 2 fludarabine 2 aldesleukin 2 Radiotherapy 2 Radiosurgery 2 Interleukin-2 2 Immunoglobulin G 2 Docetaxel 2 Bevacizumab 2 tocilizumab 1 talimogene laherparepvec 1 sargramostim 1 relatlimab 1 regorafenib 1 prednylidene 1 lutetium Lu 177 dotatate 1 lenvatinib 1 flt3 ligand protein 1 efineptakin alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583708 2025-05-23

iPRRT

Weill Medical College of Cornell University

Phase 2 Recruiting

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡